GSK-CXCR2
- CAS No.
- 211096-49-0
- Chemical Name:
- GSK-CXCR2
- Synonyms
- GSK-CXCR2;SB 265610;SB265610 >=98% (HPLC);SB-265610, 10 mM in DMSO;N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea;Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-;1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea;CXCR,nonpeptide,inhibit,Inhibitor,SB-265610,inflammation,recruitment,Delay,SB 265610,healing,neutrophil,SB265610,wound,CXC chemokine receptors
- CBNumber:
- CB71872298
- Molecular Formula:
- C14H9BrN6O
- Molecular Weight:
- 357.16
- MOL File:
- 211096-49-0.mol
- MSDS File:
- SDS
- Modify Date:
- 2025/4/28 21:36:36
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P280-P305+P351+P338 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| WGK Germany | 3 |
GSK-CXCR2 price More Price(2)
GSK-CXCR2 Chemical Properties,Uses,Production
Uses
SB 265610 is an anti-tumor pharmaceutical developed to act as an antagonist to cysteine-amino acid-cysteine (CXC) chemokines receptor 2 antagonist.
Biological Activity
Potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca 2+ mobilization (IC 50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo .
Biochem/physiol Actions
SB265610 is a potent and selective CXCR2 chemokine receptor antagonist. It has a Kd = 2.5 nM.
GSK-CXCR2 Preparation Products And Raw materials
Raw materials
Preparation Products
GSK-CXCR2 Suppliers
Global( 81)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | United States | 32239 | 58 | Inquiry |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | China | 30230 | 58 | Inquiry |
| Aromsyn Co., Ltd. | +86-0571-85585865 +8613336024896 | China | 19183 | 58 | Inquiry |
| Nantong HI-FUTURE Biology Co., Ltd. | +undefined18051384581 | China | 3135 | 58 | Inquiry |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | China | 8467 | 58 | Inquiry |
| Aladdin Scientific | United States | 57505 | 58 | Inquiry | |
| Shanghai Aladdin Biochemical Technology Co.,Ltd. | 400-6206333 13167063860 | China | 48458 | 58 | Inquiry |
| Hubei De'ao Chemical Research Pharmaceutical Technology Co., Ltd | 18502726233; 18502726233 | China | 9713 | 58 | Inquiry |
| Shanghai Perry Pharmaceutical Technology Co., Ltd | 17710868586 | China | 48 | 58 | Inquiry |
| Suzhou Haiben Pharmaceutical Co., Ltd | 14760821013 13564957716 | China | 8045 | 58 | Inquiry |
211096-49-0(GSK-CXCR2)Related Search:
chevron_left
1of4
chevron_right
GSK-CXCR2
N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea
SB 265610
1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea
Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-
SB265610 >=98% (HPLC)
CXCR,nonpeptide,inhibit,Inhibitor,SB-265610,inflammation,recruitment,Delay,SB 265610,healing,neutrophil,SB265610,wound,CXC chemokine receptors
SB-265610, 10 mM in DMSO
211096-49-0
C14H9BrN6O